natgillin/translations-raw huggingface dataset:
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
one or more ethylene oxide propylene oxide (EO-PO) block copolymers, the EO-PO block copolymers are selected from the group consisting of poloxamer 407, poloxamer 403, and a combination thereof wherein the concentration of EO-PO block copolymer is about 0.063% to 3.0%; 
Oprema sukladno patentnom zahtjevu 13, gdje je EO-PO blok kopolimera poloksamer 407 (pluronski F127) i koncentracija EO-PO bloka kopolimera je od otprilike 0,063 % do otprilike 2,0 % (m/V).
An anti-sclerostin antibody comprising a CDR-H1 of SEQ ID NO:245, a CDR-H2 of SEQ ID NO:246, a CDR-H3 of SEQ ID NO:247, a CDR-L1 of SEQ ID NO:78, a CDR-L2 of SEQ ID NO:79 and a CDR-L3 of SEQ ID NO:80, for use in a method for increasing bone mineral density in a postmenopausal woman, the method comprising administering to a postmenopausal woman suffering from osteoporosis said anti-sclerostin antibody in an amount and for a treatment period effective to increase lumbar vertebrae bone mineral density (BMD) at least 9% from pretreatment baseline at twelve months following initial administration of the anti-sclerostin antibody; wherein the amount of anti-sclerostin antibody administered is 140 mg to 210 mg and the amount of the anti-sclerostin antibody is administered at an interval no more frequent than once a month. 
Antisklerostinsko antitijelo koje sadrži CDR-H1 od SEQ ID NO:245, CDR-H2 OD SEQ ID NO:246, CDR-H3 OD SEQ ID NO:247, CDR-LA OD SEQ ID NO:78, CDR-L2 OD SEQ ID NO:79 i CDR-L3 OD SEQ ID NO:80, za primjenu u metodi za povećanje mineralne gustoće kostiju kod žene u postmenopauzi, pri čemu se metoda sastoji od primjene kod žene u postmenopauzi koja ima T ocjenu kralježaka nižu ili jednaku -2 spomenutog antiskerostinskog antitijela u količini i tijekom razdoblja liječenja učinkovitim za povećanje mineralne gustoće kostiju (BMD) lumbalnih kralježaka za najmanje 9 % u odnosu na početnu vrijednost prije liječenja dvanaest mjeseci nakon početne primjene antisklerostinskog antitijela; naznačeno time, što količina antisklerostinskog antitijela koja se primjenjuje iznosi 140 mg do 210 mg te se ta količina antisklerostinskog antitijela primjenjuje u intervalu od najviše jednom mjesečno.
a light chain comprising a human kappa light chain constant region and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:41. 
varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiselina navedenu u SEQ ID NO:38 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiselina navedenu u SEQ ID NO:41;
an antibody against epidermal growth factor receptor; 
- - protutijelo protiv receptora čimbenika rasta epiderme;
That is, the invention is as defined within the appended claims. It will be understood that the invention relates to cDNA which encodes the following: an antibody, or a functional fragment of the antibody which specifically recognizes one or more polypeptides comprising an amino acid sequence described in any one of the following (a) to (i) and inhibits osteoclast formation and/or osteoclastic bone resorption: 
Monoklonsko antitijelo ili njegov funkcionalni fragment koji specifično prepoznaju jedan ili više siglec-15 polipeptida s aminokiselinskim slijedom kodiranim nukleotidnim slijedom, koji je opisan bilo kojom od sljedećih stavki i) do 1), i koji inhibiraju razvoj osteoklasta i/ili osteoklastnu resorpciju kostiju: i) -onukleotidni slijed predstavljen kao SEQ ID NO: 1; j) -nukleotidni slijed predstavljen kao SEQ ID NO: 3; k) nukleotidni slijed predstavljen kao SEQ ID NO: 19:1
a compound of claim 27 or 29, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; or 
spoj iz bilo kojeg od zahtjeva 14, 16, 18 ili 20, ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljiv nosač; ili
In various embodiments, the invention provides a method for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome) in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a fusion protein comprising an amino acid sequence at least 85% identical to a human a-N-acetylglucosaminidase (Naglu) protein (SEQ ID NO: 1), a peptide tag having an amino acid sequence at least 70% identical to amino acids 8-67 of mature human IGF-II and a spacer peptide located between the Naglu amino acid sequence and the IGF-II peptide tag. 
Pripravak za uporabu u liječenju Mukopolisaharidoze tipa NIB (sindroma Sanfilippo B) kod subjekta koji sadrži fuzijski protein koji obuhvaća sekvencu aminokiseline koja je barem 85% identična sa ljudskim a-N- acetilglukozaminidaza proteinom (Naglu), peptidnu oznaku koja ima sekvencu aminokiseline koja je barem 70% identična aminokiselinama 8-67 od zrelog ljudskog IGF-II i razdvajajući peptid smješten između sekvence aminokiseline Naglu i peptidne oznake IGF-IL, naznačen time da razmaknica sadrži sekvencu aminokiseline GGGGS (SEQ ID NO: 12) ili GGGPS (SEQ ID NO: 14).
The method of any preceding claim, wherein the bag (20) is filled with a sample through an aperture (25,26), the aperture is sealed and the sample in the bag is frozen. The method of any preceding claim, comprising: 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se uzorak u navedenu vrećicu (20) stavlja kroz otvor (25, 26), zatim se otvor hermetički zatvara,a a uzorak u navedenoj vrećici se zamrzava.
The beta blocker may also have an intrinsic sympathomimetic activity as acebutolol, betaxolol, carteolol, carvedilol, labetalol, oxprenolol, penbutolol, pindolol, propranolol. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je beta blokator odabran iz skupine koja se sastoji od karteolola, oksprenolola, penbutolola, pindolola.
The compound of Paragraph 25, wherein said compound is selected from the group consisting of: 
Spoj prema zahtjevu 19, pri čemu navedeni spoj je izabran iz skupine koju čine:
a reference strain of E. coli bacteria and/or a reference strain of Staphylococcus aureus. The kit according to claim 38, wherein said reference strain of E. coli bacteria is E. coli ATCC 29522. 
Kit prema zahtjevu 24 gdje je standard dobiven kontaktom platforme s referentnim sojem bakterije E. coli (po izboru E. coli ATCC 29522), i/ili s referentnim sojem Staphilococcus aureus (po izboru Staphilococcus aureus
wherein, the compound of Formula (II) or (IIA) is prepared by reducing a compound of Formula (III) or (IIIA) respectively: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se spoj Formule (II) ili (ILA) dobiva reduciranjem spoja Formule (III) odnosno (IIIA):
a container that contains a pharmaceutical composition containing the peptide according to any one of claims 1 to 4, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
16. Komplet koji sadrži posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku.
is 5 to 8 amino acid residues in length; 
L, je duljine 5 do 6 ostataka amino kiseline;
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereoisomeric mixture (R,S+S,S) 
I) reakciju 2,2-dimetil-1,5dioksolan-4-karbaldehida formule EN DE) s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+S, S)
Figure 9 is a perspective view of an exemplary embodiment of blender container base; 
Slika 9 = prikazje primjera ostvarenja baze posude mješalice;
A compound according to claim 1 that is 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time što je farmaceutski prihvatljiva sol of 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on.
The method of claim 1, wherein the cancer is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system. The method of claim 2, wherein the cancer is melanoma. The method of claim 3, wherein the cancer is metastatic melanoma. 
Spoj za uporabu u postupku liječenja prema zahtjevu 8 ili uporaba prema zahtjevu 9, naznačen(a) time, da se rak koji treba liječiti, odabire iz skupine koju čine: karcinom pluća, karcinom pankreasa, karcinom mjehura, karcinom debelog crijeva, mijeloidni poremećaji, rak prostate, tiroidni rak, melanom, te adenomi i karcinomi jajnika, oka, jetre, bilijarnog stabla i nervnog sustava.
A method according to claim 5 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time se što bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična začepljenost dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.
a supply unit (2, 250, 280) for supplying injection fluid to the cartridge comprising an injection support (4) comprising injection means (5, 550, 580) for injecting injection fluid into the cartridge, 
L Uređaj za pripravu tekućine pogodne za ishranu, koji se sastoji od: - opskrbne jedinice (2, 200, 250, 280) za injektiranje tekućine u kapsulu (10, 100),
the costimulatory 4-1 BB signalling region comprises the amino acid sequence of SEO ID NO: 23; 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
The therapeutic nanoparticle of embodiment 36, wherein the hydrophobic acid is pamoic acid. 
Terapijska nanočestica u skladu s patentnim zahtjevom 8, naznačena time što je hidrofobna kiselina pamoinska kiselina.
The method of manufacture of the evertable catheter tube (10) according to any one of the claims 11 to 13, wherein the method further comprises a subsequent step of coating a primary outer surface (16) of the evertable catheter tube (10) with a lubrication material. 
Postupak izrade reverzibilne kateterske cijevi (10) prema bilo kojem od zahtjeva 11 do 13 pri čemu postupak nadalje obuhvaća naknadni korak premazivanja primarne vanjske površine (16) reverzibilne kateterske cijevi (10) premazom.
A CAR according to any one of paras 1 to 3 wherein the spacer consists of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or a sequence at least 90% identical thereto. 
CAR prema patentnom zahtjevu 9 naznačen time što razmaknica sadrži sekvencu koja je odabrana iz skupine koja se sastoji od SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 ili SEQ ID NO:7 ili a sekvencu koja je njoj najmanje 90% identična.
A process for preparing a pharmaceutical composition, comprising admixing a compound or a pharmaceutically acceptable salt thereof according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients. 
Postupak priprave farmaceutskog pripravka, naznačen time što se sastoji u miješanju spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1-12 s jednim ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
Adult rats of the Sprague-Dawley strain are used. 
Rabljeni su odrasli štakori soja Sprague-Dawley.
An isolated nucleotide sequence selected from the group consisting of the sequences set forth as SEQ ID NOs: 3, 6, and 21, wherein said isolated nucleotide sequences are markers useful for detecting the Ms allele, ms allel, Rf allele and/or rf allele in Brassica germplasm and the associated phenotypes. 
. Izolirana nukleotidna sekvenca odabrana iz skupine koja se sastoji od sekvenci navedenih kao SEQ ID NOg: 3, 6,1 21, naznačena time da su navedene izolirane nukleotidne sekvence markeri korisni za detekciju Ms alela, ms alela, Rf alela iili rf alela u Brassica germplazmi i srodnim fenotipovima.
Ethyl acetate (200 ml) was added to the residue and the solution washed with water (2 x 50 ml). 
Ostatku se doda etil acetat (200 ml) i otopina se ispere vodom (2 x 50 ml).
A polynucleotide encoding a modified lecithin-cholesterol acyltransferase (LCAT) protein comprising a modification of the mature human LCAT amino acid sequence set out in SEQ ID NO: 1, wherein the modification to the LCAT amino acid sequence consists of a substitution at amino acid residue C31 selected from the group consisting of, C31I, C31M, C31F, C31V, C31W, C31Y, C31 R and C31H. 
Modificirani protein lecitin-kolesterol aciltransferaza (LCAT), naznačen time što modificirani LCAT protein sadrži modifikaciju aminokiselinske sekvence zrelog LCAT navedenog u SEQ ID NO: 1; ili SEQ ID NO: 2 kao što je navedena na Sl. 2; i modifikacija se sastoji od supstitucije na aminokiselinskom ostatku C31 izabranom iz grupe koju čine C31I, C31M, C31F, C31V, C31W, C31Y, C31R i C31H.
A combination according to claim 1 or 2 characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da djelatni sastojci (a) 1 (b) čine jedinstveni farmaceutski pripravak.
If an object is inserted it may not be possible to move the retaining member towards the non-retaining position. 
Ako se neki predmet umetne može biti onemogućeno da se pomakne član za držanje prema položaju kada on ne drži.
A kit according to claim 9, characterized in that the therapeutic component (1 b) is selected from the group consisting of a reservoir for active agent, a metallic wire and a combination thereof. 
Set prema zahtjevu 9, naznačen time što se terapijska komponenta (1b) izabire iz grupe koja obuhvaća spremnik djelatne tvari, metalnu žicu i njihovu kombinaciju.
Many people have difficulty processing lactose, for instance. 
Mnogi ljudi imaju problema s preradom laktoze, na primjer.
Y is phenyl substituted with alkynyl, or fused with another 3-8 membered ring; and 
Y je fenil supstituiran sa alkinilom, ili spojen sa drugim prstenom od 3-8 članova; te
Basic design of equipment depends on the process design but the detailed equipment design can be different in order to meet PED, ASME or other local design codes or local state of the art technology. Method to store or increase the energy content of a reaction mixture by means of an endothermic condensation reaction, said reaction mixture comprising an inorganic oxoacid compound and/or its salt and water, said reaction being enabled by the heat input from a heat source distinct from said reaction mixture. 
HR P20160021 T1 PATENTNI ZAHTJEVI Postupak za skladištenje ili povećanje sadržaja energije reakcijske smjese, pri čemu je spomenuta reakcija omogućena dovođenjem energije iz izvora topline koji nije identičan sa spomenutom reakcijskom smjesom, naznačen time što se sadržaj energije reakcijske smjese skladišti ili povećava endotermnom reakcijom kondenzacije, pri čemu spomenuta reakcijska smjesa sadrži neorganski oksokiselinski spoj i/ili njegovu sol i vodu.
The mixture was transferred to a fluidization rotogranulator (Glatt GPCG1), and a mixture of 20 g of 35% dimethyl polysiloxane emulsion and 1000 ml of ion-exchanged water was sprayed onto it. 
Smjesa je prenesena u fluidizacijski rotacijski granulator (Glatt GPCG1), pa je na nju raspršena smjesa 20 g 35% emulzije dimetil polisiloksana i 1000 ml ionskoizmjenjivačke vode.
Substituent R2 is selected from the group consisting of H, straight or branched (C1-C6) alkyl, and (C1-C6)alkyl-C(O)—. 
R? je odabran iz skupine koju čine H, ravnolančani ili razgranati (Cy-Cg)alkil, i (Ci-Cs)alkil-C(O)-;
from about 45% to about 50% by weight on a dry weight basis of a pharmaceutically acceptable microcrystalline cellulose; 
11) od 45 do 50 masenih postotaka na bazi suhe mase farmaceutski prihvatljive mikrokristalne celuloze;
reacting a compound of formula (3) wherein 
(a) reakciju spoja formule (3) e
Panel according to one of the foregoing claims, wherein the second locking element is positioned at a distance from an upper side of the downward groove. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu je drugi element (30, 69) za zaključavanje izveden na udaljenosti od gornje stranice prema dole usmjerenog žlijeba (27, 68).
selecting (406) a guide bushing having a desired predetermined clearance with respect to the bar stock, said clearance providing a related harmonic level, said harmonic level configured to impart a controlled milling effect to the loaded bar stock by allowing the same to vibrate while within the bar feeder; 
odabir (406) vodiča sa željenim prethodno određeni razmakom u odnosu na materijal, razmak omogućava povezanu harmoničnu razinu, harmonična razina je oblikovana na način da djeluje kontroliranim efektom mljevenja na materijal omogućujući da isti vibrira dok je unutar opskrbljivača;
EP 338,745 (Owens, et al.); and European Patent Application Publication No. 
06.10.2011. (97) Broj objave europske prijave patenta: EP 2552966 A1
The reaction mixture was filtered, concentrated in vacuo and purified by reverse phase HPLC to give the title compound. 
Reakcijska smjesa se filtrira, koncentrira in vacuo i pročisti obrnuto faznom HPLC da bi se dobio naslovni spoj.
The process according to claim 8, wherein said palladium source is Pd(dba)2 or Pd(OAc)2. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je navedeni izvor paladija Pd(dba), ili PA(OAc),.
the sheet or web, sufficiently close to the engraved, magnetized surface of the said body. 
list ili tkanina, dovode dovoljno blizu ugraviranoj magnetiziranoj površini navedenog tijela.
With the exception of Metformin, an antidiabetic agent with multiple effects including gluconeogenesis inhibition, most inhibitors have failed to reduce HGP and plasma glucose levels in humans caused by hepatic autoregulation, a compensatory increase in hepatic glycogenolysis that maintains a high rate of HGP (Yki-Javinen, 1994). 
Uz iznimku meformina, antidijabetička sredstva s višestrukim učincima uključuju inhibiciju glukoneogeneze, većina inhibitora nije uspjela smanjiti HGP i razinu glukoze u plazmi u ljudi uzrokovanu jetrenom autoregulacijom, kompenzacijskim povećanjem jetrene glikogenolize koja održava veliku brzinu HGP (Yki-Javinen, 1994).
one or more ethylene oxide propylene oxide (EO-PO) block copolymers, the EO-PO block copolymers comprising poloxamer 407, poloxamer 403, or a combination thereof, wherein the concentration of the EO-PO block copolymer is from 0.001% to 3.0% (w/v); 
Oprema sukladno patentnom zahtjevu 13, gdje je EO-PO blok kopolimera poloksamer 407 (pluronski F127) i koncentracija EO-PO bloka kopolimera je od otprilike 0,063 % do otprilike 2,0 % (m/V).
According to a preferred embodiment of the present invention said cell is a yeast cell, preferably a methylotrophic yeast cell. Preferably the methylotrophic yeast cell is selected from the group consisting of Candida, Hansenula, Pichia and Toruplosis, especially a Pichia pastoris cell. 
Postupak prema zahtjevu 11, naznačen time, da spomenuta stanica je stanica kvasca, najbolje metilotrofička stanica kvasca, prednosno odabrana iz skupine koja se sastoji od stanica Candida, Hansenula, Pichia i Toruplosis, posebno stanica Pichia pastoris.
The composition, separate dosage forms or package according to any of claims 7-14, comprising 10-60 mg of the compound of Formula I or pharmaceutically acceptable salt thereof, and 2.5-30 mg quinidine. 
Sastav, zasebni oblici doziranja ili pakiranje u skladu s patentnim zahtjevima 11-17, koji obuhvaćaju 10-60 mg tvari formule I ili njene farmaceutski prihvatljive soli, i 2.5-30 mg kinidina.
is a hydrogen atom; a substituted or unsubstituted straight or branched C1-C6 alkyl group; a halogen atom; a substituted or unsubstituted straight or branched C1-C6 alkoxy group; or a substituted or unsubstituted straight or branched C1-C4 thioalkyl group; and R4 are each independently a hydrogen atom, or a C1-C2 alkyl group; and in the case of the substituted alkyl, the substituted alkoxy, and the substituted thioalkyl, the substituent is a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group. 
je atom vodika; ravna ili razgranata C1-C6 alkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom; atom halogena; ravna ili razgranata C1-C6 alkoksi grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom; ili ravna ili razgranata C1-C4 tioalkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom;
In one embodiment, the invention provides a method for preparing a composition comprising pravastatin sodium having less than about 0.1 % by weight pravastatin C. The method includes starting with a compactin sample comprising a sufficiently low level of compactin C. Preferably, the amount of compactin C in the compactin sample is less than about 0.16% by weight. 
U jednom ostvarenju izum daje postupak pripreme smjese koja sadrži pravastatinnatrij s manje od 0.1% masenog udjela pravastatina C. Postupak započinje s uzorkom kompaktina koji sadrži dovoljno nisku količinu kompaktina C. Poželjno, količina kompaktina C u uzorku kompaktina je manja od 16% težine.
However, several peptidic antagonists with low histamine release properties have been reported, although they still must be delivered via sustained delivery routes (such as subcutaneous injection or intranasal spray) due to limited bioavailability. 
Međutim, nađeno je nekoliko peptidnih antagonista sa svojstvom niskog otpuštanja histamina, iako se i njih mora unositi sredstvima za produljeni unos (poput supkutane injekcije ili intranazalnog spreja), zbog ograničene biodostupnosti.
The DNA of claim 5, which comprises the polynucleotide having the nucleotide sequence of SEQ ID NO: 14 encoding the amino acid sequence of SEQ ID NO: 7; and which comprises the polynucleotide having the nucleotide sequence of SEQ ID NO: 18 encoding the amino acid sequence of SEQ ID NO: 8. 
DNA u skladu s patentnim zahtjevom 5, naznačena time što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 14, koji kodira aminokiselinski slijed sa SEQ ID NO: 7; te što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 18, koji kodira aminokiselinski slijed sa SEQ ID NO: 8.
A compound according to claim 7, where Z is CO2Q, Q is hydrogen, and m is 1, 2, or 3. 
Tvar u skladu s patentnim zahtjevom 7, pri čemu je Z jednak CO2Q, Q je vodik, a mje 1, 2, ili 3.
mg coating. A tablet for oral administration consisting of 180 mg deferasirox; 
Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da se ona sastoji od: 180 mg deferasiroksa;
Pure fractions were evaporated to dryness to afford (S)-3-amino-3-(4-chlorophenyl)propan-1-ol (5.76 g, 61.9%) as a white solid. 
Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži reakciju kiseline Formule (II) i (S)-3-amino-3-(4-klorofenil)propan-1 -ola:
The compounds have the general Formula I 
Spojevi imaju opću Formulu I